1 Ocak 2019 Dergi makalesi Açık Erişim

Nayman, Ayse Hande; Siginc, Halime; Zemheri, Ebru; Yencilek, Faruk; Yildirim, Asif; Telci, Dilek

Citation Style Language JSON

{
  "DOI": "10.7150/jca.29192", 
  "abstract": "Renal cell carcinoma (RCC) is the predominant type of kidney cancer. Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients. The clinical limitation confronted during everolimus therapy is the onset of drug resistance that decreases the efficacy of the drug. Elevated level of anti-apoptotic Bcl-2 protein is proposed to be an emerging feedback loop for the acquired drug-resistance in various cancer types. In this study, the Bcl-2 inhibitor ABT-737 was used in combination with everolimus to enhance its anti-tumor effectiveness in everolimus-resistant RCC cell lines. Everolimus and ABT-737 combination synergistically led to a decrease in the proliferation of primary site A-498 and metastatic site Caki-1 RCC cell lines, which was accompanied by a reduction in protein levels of cell cycle and mTOR pathway proteins. In both RCC cell lines, everolimus-ABT-737 combination not only induced apoptosis, caspase and PARP-1 cleavage but also a decrease in Bcl-2 protein levels in parallel with a concomitant increase in Bim and Noxa levels.", 
  "author": [
    {
      "family": "Nayman", 
      "given": " Ayse Hande"
    }, 
    {
      "family": "Siginc", 
      "given": " Halime"
    }, 
    {
      "family": "Zemheri", 
      "given": " Ebru"
    }, 
    {
      "family": "Yencilek", 
      "given": " Faruk"
    }, 
    {
      "family": "Yildirim", 
      "given": " Asif"
    }, 
    {
      "family": "Telci", 
      "given": " Dilek"
    }
  ], 
  "container_title": "JOURNAL OF CANCER", 
  "id": "69817", 
  "issue": "6", 
  "issued": {
    "date-parts": [
      [
        2019, 
        1, 
        1
      ]
    ]
  }, 
  "page": "1466-1478", 
  "title": "Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo", 
  "type": "article-journal", 
  "volume": "10"
}